Logo image
Methioninase gene therapy
Journal article

Methioninase gene therapy

Robert M. Hoffman, Kenji Miki, Waddah Al-Refaie, Mingxu Xu and Yuying Tan
Methods in Molecular Biology, Vol.1866
2019

Abstract

Adenoviridae Animals Apoptosis Bystander Effect Carbon-Sulfur Lyases Cell Line, Tumor Cytochromes c Genetic Therapy Green Fluorescent Proteins Humans Methionine Mice, Nude Mitochondria Permeability Plasmids Proto-Oncogene Proteins c-bcl-2 Rats Recombinant Proteins Selenomethionine Tumor Burden caspase cytochrome c doxorubicin green fluorescent protein methylselenol protein bcl 2 recombinant methionine gamma lyase retrovirus vector staurosporine toxic substance unclassified drug cytochrome c L-methionine gamma-lyase lyase methionine protein bcl 2 recombinant protein selenomethionine A-549 cell line animal experiment animal model apoptosis bystander effect cancer inhibition cancer resistance cancer survival controlled study cytosol drug efficacy enzyme activation female gene fusion genetic transduction HT-1080 cell line human human cell in vitro study in vivo study mitochondrial respiration mouse nonhuman oxidative stress protein expression Pseudomonas putida Retroviridae synergistic effect viral gene delivery system viral gene therapy Adenoviridae animal biosynthesis gene therapy genetics metabolism mitochondrion nude mouse permeability plasmid procedures rat tumor cell line tumor volume
Recombinant methioninase (rMETase) derived from Pseudomonas putida targets the elevated methionine (MET) requirement of cancer cells (methionine dependence) and has shown efficacy against a variety of cancer types in mouse models. To enhance the efficacy of rMETase, we constructed the pLGFP-METSN retrovirus encoding the P. putida methioninase (METase) gene fused with the green fluorescent protein (GFP) gene. pLGFP-METSN or control vector pLGFPSN was introduced into the human lung cancer cell line H460. The retrovirus-mediated METase gene transfer decreased the intracellular MET level of the cancer cells and consequently enhanced the efficacy of treatment with the rMETase protein. The rMETase gene was introduced into an adenovirus. rAd-METase transduction of human OVACAR-8 ovarian cancer cells and human fibrosarcoma HT1080 cells in vitro and in vivo resulted in high levels of METase expression up to 10% or more of the total protein of the cells, depending on the multiplicity of infection. The combination of rAd-METase and rMETase was synergistic to kill these cells. Normal fibroblasts, on the other hand, appeared relatively resistant to the METase gene in the presence of rMETase. Adenoviral METase-transduced cancer cells were used in combination with selenomethionine, releasing highly toxic methylselenol, which killed both the cancer cells containing the METase gene and bystanders. Methylselenol damaged the mitochondria via oxidative stress and caused cytochrome c release into the cytosol, thereby activating the caspase cascade and cancer-cell apoptosis. Adenoviral METase-gene/SeMET treatment also inhibited tumor growth in rodents and significantly prolonged their survival. AdMETase/SeMET therapy was effective against Bcl-2-overproducing A549 lung cancer cells, which were resistant to staurosporine-induced apoptosis, with a strong bystander effect. The combination of Ad-METase/SeMET and doxorubicin (DOX) delayed the growth of the H460 human lung cancer, growing subcutaneously in nude mice. These results demonstrate the potential of methionine restriction (MR) for cancer treatment. © Springer Science+Business Media, LLC, part of Springer Nature 2019.

Metrics

8 Record Views

Details

Logo image